GT is pleased to have achieved a win on behalf of our client Teva Pharmaceuticals USA, Inc.
In May 2018, a U.S. Federal District Court Judge from the Central District of California granted Teva’s motion to dismiss in its entirety without leave to amend.
In April 2017, Plaintiffs commenced an action in California’s Riverside County Superior Court against Teva related to the anti-depressant drug Lexapro and its generic equivalent. That original case was removed to federal court where an initial motion to dismiss was granted with leave to amend in November 2017 though the Order agreed with Teva and outlined the many infirmities of Plaintiffs’ claims allowing for an opportunity to address them in a further amendment. After Teva raised several separate bases for dismissal, the Court finally granted the motion without further leave to amend.
GT Team: The team included Lori G. Cohen (Shareholder, Atlanta, Pharmaceutical, Medical Device & Health Care Litigation), Ginger Pigott (Shareholder, Los Angeles, Litigation), R. Scott Mullen (Associate, Los Angeles, Litigation), and Kathryn A. Guenther (Paralegal, Los Angeles, Litigation).
Greenberg Traurig’s Tel Aviv office is the only major international law firm with a multidisciplinary, registered office in Tel Aviv and serves as a gateway for Israeli businesses and entrepreneurs seeking opportunities around the world, as well as for clients exploring opportunities within Israel.